<DOC>
	<DOCNO>NCT02028377</DOCNO>
	<brief_summary>This study use PET/MRI patient adenocarcinoma pancreas identify hide metastatic disease identify patient borderline locally advanced disease .</brief_summary>
	<brief_title>Evaluation PET/MRI Patients With Pancreatic Adenocarcinoma</brief_title>
	<detailed_description>Patients receive PET/MRI scan within 6 week standard care image . There maximum number scan research . The number scan depend patient 's treatment plan .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Presence suspicious lesion pancreas consistent pancreatic adenocarcinoma . Cytological confirmation require . Patients prepare receive therapy pancreas cancer , include patient enrol NCT01413022 Patient must 18 year old Patient must life expectancy 6 month performance status 2 le Patient must able understand willing sign approve write informed consent document Women childbearing potential men must agree use adequate contraception prior study entry length study Patients enrol Clinical trials.gov # NCT01413022 trial must meet study eligibility criterion . Patient must prior resection pancreatic adenocarcinoma . Patient must history malignancy less equal 5 year previous exception basal cell squamous cell carcinoma skin treat local resection carcinoma situ cervix Patient must unable receive PETMRI scan due renal function , allergy problem receive tolerate MRI scan , etc . All patient fill standard MRI screen form . Patients must blood glucose great equal 200mg/dL time PETMRI patient diabetic glucose control . At discretion PI authorize user approval prior 2 [ 18 ] fluoro2deoxyDglucose ( FDG ) injection , patient blood glucose â‰¥ 200 mg/dL may participate study . Patient must pregnant and/or breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Adenocarcinoma</keyword>
	<keyword>image</keyword>
	<keyword>PET</keyword>
	<keyword>MRI</keyword>
</DOC>